NLRX1 acts as tumor suppressor by regulating TNF-α induced apoptosis and metabolism in cancer cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 5, 2015, Pages 1073-1086

  Singh, Kritarth ^a,b   Poteryakhina, Anastasia ^c   Zheltukhin, Andrei ^c   Bhatelia, Khyati ^a,b   Prajapati, Paresh ^a,b   Sripada, Lakshmi ^a,b   Tomar, Dhanendra ^a   Singh, Rochika ^a   Singh, Arun K ^a   Chumakov, Peter M ^c   Singh, Rajesh ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b Indian Institute of Advanced Research   (India)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

Cancer; Caspase 8; Inflammation; Metabolic reprogramming; Mitochondria; NLRX1

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 8; MITOCHONDRIAL PROTEIN; PROTEIN NLRX1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; MULTIENZYME COMPLEX; NLRX1 PROTEIN, HUMAN; PROTEIN BINDING; ROTENONE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL DEATH; CELL METABOLISM; CELL MIGRATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; CARCINOGENESIS; CELL CLONE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

MUS MUSCULUS;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; CARCINOGENESIS; CASPASE 8; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CLONE CELLS; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ENZYME ACTIVATION; HUMANS; MICE, NUDE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; REACTIVE OXYGEN SPECIES; ROTENONE; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

EID: 84923366368     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.01.016     Document Type: Article

References (56)

1. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., Caviglia J.M., Khiabanian H., Adeyemi A., Bataller R., Lefkowitch J.H., Bower M., Friedman R., Sartor R.B., Rabadan R., Schwabe R.F. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
2. Robertson F.M., Bondy M., Yang W., Yamauchi H., Wiggins S., Kamrudin S., Krishnamurthy S., Le-Petross H., Bidaut L., Player A.N., Barsky S.H., Woodward W.A., Buchholz T., Lucci A., Ueno N.T., Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J. Clin. 2010, 60:351-375.
3. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114. (e2105).
4. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001, 345:784-789.
5. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013, 14:e218-e228.
6. Ashizawa T., Okada R., Suzuki Y., Takagi M., Yamazaki T., Sumi T., Aoki T., Ohnuma S., Aoki T. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Japan. Gastric Cancer Assoc. 2005, 8:124-131.
7. Ikeguchi M., Hatada T., Yamamoto M., Miyake T., Matsunaga T., Fukumoto Y., Yamada Y., Fukuda K., Saito H., Tatebe S. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Japan. Gastric Cancer Assoc. 2009, 12:95-100.
8. Kawabata T., Ichikura T., Majima T., Seki S., Chochi K., Takayama E., Hiraide H., Mochizuki H. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 2001, 92:2050-2055.
9. Kayacan O., Karnak D., Beder S., Gullu E., Tutkak H., Senler F.C., Koksal D. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am. J. Clin. Oncol. 2006, 29:328-335.
10. Kozlowski L., Zakrzewska I., Tokajuk P., Wojtukiewicz M.Z. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz. Akad. Med. Bialymst. 2003, 48:82-84.
11. Lee J.C., Lee K.M., Kim D.W., Heo D.S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 2004, 172:7335-7340.
12. Lin Y., Kikuchi S., Obata Y., Yagyu K., Tokyo C. Research group on prevention of gastric, serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J. Gastroenterol. Hepatol. 2006, 21:432-437.
13. Nikiteas N.I., Tzanakis N., Gazouli M., Rallis G., Daniilidis K., Theodoropoulos G., Kostakis A., Peros G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J. Gastroenterol. WJG 2005, 11:1639-1643.
14. Ren Y., Poon R.T., Tsui H.T., Chen W.H., Li Z., Lau C., Yu W.C., Fan S.T. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2003, 9:5996-6001.
15. Shim K.S., Kim K.H., Han W.S., Park E.B. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999, 85:554-561.
16. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
17. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
18. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
19. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703.
20. Benchoua A., Couriaud C., Guegan C., Tartier L., Couvert P., Friocourt G., Chelly J., Menissier-de Murcia J., Onteniente B. Active caspase-8 translocates into the nucleus of apoptotic cells to inactivate poly(ADP-ribose) polymerase-2. J. Biol. Chem. 2002, 277:34217-34222.
21. Scorrano L. Caspase-8 goes cardiolipin: a new platform to provide mitochondria with microdomains of apoptotic signals?. J. Cell Biol. 2008, 183:579-581.
22. Chandra D., Choy G., Deng X., Bhatia B., Daniel P., Tang D.G. Association of active Caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving BAP31 and Caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death. Mol. Cell. Biol. 2004, 24:6592-6607.
23. Kim J.J., Lee S.B., Park J.K., Yoo Y.D. TNF-alpha-induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-X(L). Cell Death Differ. 2010, 17:1420-1434.
24. Nohl H., Gille L., Staniek K. Intracellular generation of reactive oxygen species by mitochondria. Biochem. Pharmacol. 2005, 69:719-723.
25. Gottlieb E., Vander Heiden M.G., Thompson C.B. Bcl-x(L) prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor alpha-induced apoptosis. Mol. Cell. Biol. 2000, 20:5680-5689.
26. Straus D.S. TNFalpha and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol. Cancer 2013, 12:78.
27. Arnoult D., Soares F., Tattoli I., Girardin S.E. Mitochondria in innate immunity. EMBO Rep. 2011, 12:901-910.
28. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
29. Zhao Y., Sun X., Nie X., Sun L., Tang T.S., Chen D., Sun Q. COX5B regulates MAVS-mediated antiviral signaling through interaction with ATG5 and repressing ROS production. PLoS Pathog. 2012, 8:e1003086.
30. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455:674-678.
31. Bhatelia K., Singh A., Tomar D., Singh K., Sripada L., Chagtoo M., Prajapati P., Singh R., Godbole M.M., Singh R. Antiviral signaling protein MITA acts as a tumor suppressor in breast cancer by regulating NF-kappaB induced cell death. Biochim. Biophys. Acta 2014, 1842:144-153.
32. Moore C.B., Bergstralh D.T., Duncan J.A., Lei Y., Morrison T.E., Zimmermann A.G., Accavitti-Loper M.A., Madden V.J., Sun L., Ye Z., Lich J.D., Heise M.T., Chen Z., Ting J.P. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 2008, 451:573-577.
33. Xia X., Cui J., Wang H.Y., Zhu L., Matsueda S., Wang Q., Yang X., Hong J., Songyang Z., Chen Z.J., Wang R.F. NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity 2011, 34:843-853.
34. Sripada L., Tomar D., Prajapati P., Singh R., Singh A.K., Singh R. Systematic analysis of small RNAs associated with human mitochondria by deep sequencing: detailed analysis of mitochondrial associated miRNA. PLoS ONE 2012, 7:e44873.
35. Tomar D., Prajapati P., Sripada L., Singh K., Singh R., Singh A.K., Singh R. TRIM13 regulates Caspase-8 ubiquitination, translocation to autophagosomes and activation during ER stress induced cell death. Biochim. Biophys. Acta 2013, 1833:3134-3144.
36. Cheng T., Sudderth J., Yang C., Mullen A.R., Jin E.S., Mates J.M., DeBerardinis R.J. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:8674-8679.
37. D'Amours D., Sallmann F.R., Dixit V.M., Poirier G.G. Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis. J. Cell Sci. 2001, 114:3771-3778.
38. Soares F., Tattoli I., Rahman M.A., Robertson S.J., Belcheva A., Liu D., Streutker C., Winer S., Winer D.A., Martin A., Philpott D.J., Arnoult D., Girardin S.E. The mitochondrial protein NLRX1 controls the balance between extrinsic and intrinsic apoptosis. J. Biol. Chem. 2014, 289:19317-19330.
39. Gonzalvez F., Lawrence D., Yang B., Yee S., Pitti R., Marsters S., Pham V.C., Stephan J.P., Lill J., Ashkenazi A. TRAF2 sets a threshold for extrinsic apoptosis by tagging Caspase-8 with a ubiquitin shutoff timer. Mol. Cell 2012, 48:888-899.
40. Jin Z., Li Y., Pitti R., Lawrence D., Pham V.C., Lill J.R., Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of Caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137:721-735.
41. Huai J., Vogtle F.N., Jockel L., Li Y., Kiefer T., Ricci J.E., Borner C. TNFalpha-induced lysosomal membrane permeability is downstream of MOMP and triggered by caspase-mediated NDUFS1 cleavage and ROS formation. J. Cell Sci. 2013, 126:4015-4025.
42. Hamanaka R.B., Chandel N.S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem. Sci. 2010, 35:505-513.
43. Lopez-Hernandez F.J., Ortiz M.A., Bayon Y., Piedrafita F.J. Z-FA-fmk inhibits effector caspases but not initiator caspases 8 and 10, and demonstrates that novel anticancer retinoid-related molecules induce apoptosis via the intrinsic pathway. Mol. Cancer Ther. 2003, 2:255-263.
44. Geiger T., Wehner A., Schaab C., Cox J., Mann M. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol. Cell. Proteomics MCP 2012, 11:014050. (M111).
45. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
46. Tattoli I., Carneiro L.A., Jehanno M., Magalhaes J.G., Shu Y., Philpott D.J., Arnoult D., Girardin S.E. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production. EMBO Rep. 2008, 9:293-300.
47. Schug Z.T., Gonzalvez F., Houtkooper R.H., Vaz F.M., Gottlieb E. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ. 2011, 18:538-548.
48. Lanning N.J., Looyenga B.D., Kauffman A.L., Niemi N.M., Sudderth J., DeBerardinis R.J., MacKeigan J.P. A mitochondrial RNAi screen defines cellular bioenergetic determinants and identifies an adenylate kinase as a key regulator of ATP levels. Cell Rep. 2014, 7:907-917.
49. Arnoult D., Soares F., Tattoli I., Castanier C., Philpott D.J., Girardin S.E. An N-terminal addressing sequence targets NLRX1 to the mitochondrial matrix. J. Cell Sci. 2009, 122:3161-3168.
50. He G., Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011, 21:159-168.
51. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
52. Zhang D.W., Shao J., Lin J., Zhang N., Lu B.J., Lin S.C., Dong M.Q., Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336.
53. Maycotte P., Gearheart C.M., Barnard R., Aryal S., Mulcahy Levy J.M., Fosmire S.P., Hansen R.J., Morgan M.J., Porter C.C., Gustafson D.L., Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014, 74:2579-2590.
54. Lei Y., Wen H., Yu Y., Taxman D.J., Zhang L., Widman D.G., Swanson K.V., Wen K.W., Damania B., Moore C.B., Giguere P.M., Siderovski D.P., Hiscott J., Razani B., Semenkovich C.F., Chen X., Ting J.P. The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy. Immunity 2012, 36:933-946.
55. Cleary A.S., Leonard T.L., Gestl S.A., Gunther E.J. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014, 508:113-117.
56. Bhatelia K., Singh K., Singh R. TLRs: Linking inflammation and breast cancer. Cell. Signal. 2014, 26:2350-2357.